Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Crohn’s Disease and Ulcerative Colitis | TreatmentTrends | US | 2015

Login to access report north_east
Contact sales account_box

Crohn’s disease (CD) and ulcerative colitis (UC) are chronic relapsing/remitting inflammatory diseases of the gastrointestinal tract that typically manifest symptoms including diarrhea, abdominal pain, and weight loss. The TreatmentTrends: Crohn’s Disease and Ulcerative Colitis 2015 (US) report provides valuable insights into the market dynamics and competitive landscape of these conditions through comprehensive primary market research with U.S. gastroenterologists who treat patients with these diseases. The report focuses on current use of biological products prescribed for CD/UC, their patient share, strengths and weaknesses of key brands, barriers to broader usage of biological agents, and gastroenterologists’ awareness of and interest in key emerging therapies.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east
Report
Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics / targeted oral therapies. The well-established TNF-alpha…
north_east
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
north_east
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
north_east
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east